Insulin glulisine: Difference between revisions
Content deleted Content added
No edit summary |
m ISBNs (Build KC) |
||
| Line 1: | Line 1: | ||
{{ |
{{Expert-subject|Pharmacology|date=March 2010}} |
||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Line 46: | Line 46: | ||
| molecular_weight = 5823 g/mol |
| molecular_weight = 5823 g/mol |
||
}} |
}} |
||
'''Insulin glulisine''' is a rapid-acting [[insulin analogue]] that differs from human [[insulin]] in that the amino acid [[asparagine]] at position B3 is replaced by [[lysine]] and the lysine in position B29 is replaced by [[glutamic acid]].<ref>DailyMed: [http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=7137 apidra (insulin glulisine) injection, solution]</ref> It was developed by [[Sanofi-Aventis]] and sold under the trade name '''Apidra'''.<ref>{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|isbn=3-85200-181-4|language=German}}</ref> When injected subcutaneously, it appears in the blood earlier than human insulin.<ref>{{cite doi|10.2165/00003495-200969080-00006}}</ref> When used as a meal time insulin, the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.<ref>Drugs.com: [http://www.drugs.com/monograph/insulin-glulisine.html Insulin Glulisine]</ref> Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional<ref>{{cite web|first=Sanofi|title=Sanofi Prescription Products|url=http://products.sanofi.us/apidra/apidra.pdf|publisher=Sanofi|accessdate=21 April 2012}}</ref> . |
'''Insulin glulisine''' is a rapid-acting [[insulin analogue]] that differs from human [[insulin]] in that the amino acid [[asparagine]] at position B3 is replaced by [[lysine]] and the lysine in position B29 is replaced by [[glutamic acid]].<ref>DailyMed: [http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=7137 apidra (insulin glulisine) injection, solution]</ref> It was developed by [[Sanofi-Aventis]] and sold under the trade name '''Apidra'''.<ref>{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|isbn=3-85200-181-4 {{Please check ISBN|reason=Check digit (4) does not correspond to calculated figure.}}|language=German}}</ref> When injected subcutaneously, it appears in the blood earlier than human insulin.<ref>{{cite doi|10.2165/00003495-200969080-00006}}</ref> When used as a meal time insulin, the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.<ref>Drugs.com: [http://www.drugs.com/monograph/insulin-glulisine.html Insulin Glulisine]</ref> Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional<ref>{{cite web|first=Sanofi|title=Sanofi Prescription Products|url=http://products.sanofi.us/apidra/apidra.pdf|publisher=Sanofi|accessdate=21 April 2012}}</ref> . |
||
==References== |
==References== |
||
Revision as of 23:29, 5 May 2012
 | This article needs attention from an expert in Pharmacology. Please add a reason or a talk parameter to this template to explain the issue with the article. (March 2010) |
| Clinical data | |
|---|---|
| Trade names | Apidra |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607033 |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C258H384N64O78S6 |
| Molar mass | 5823 g/mol g·mol−1 |
  (what is this?) (verify) | |
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.[4] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional[5] .
References
- ^ DailyMed: apidra (insulin glulisine) injection, solution
- ^ Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN [[Special:BookSources/3-85200-181-4 |3-85200-181-4 [[Category:Articles with invalid ISBNs]]]].
{{cite book}}: Check|isbn=value: invalid character (help) - ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.2165/00003495-200969080-00006, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.2165/00003495-200969080-00006instead. - ^ Drugs.com: Insulin Glulisine
- ^ "Sanofi Prescription Products" (PDF). Sanofi. Retrieved 21 April 2012.
{{cite web}}:|first=missing|last=(help)
External links
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |